Axel Bolte Healthcare News

This is selected healthcare news for Axel Bolte, which is filed under People. There are 61 news items for this page. A press release filter page is also available for Axel Bolte.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/1/2022 Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
Inozyme Pharma Inc. BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will ...
Yahoo News
12/1/2022 2022-12-01 | NDAQ:INZY | Press Release | Inozyme Pharma Inc.
INZY 33 minutes ago BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive ...
stockhouse.com
12/1/2022 Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a ...
inyoregister.com
12/1/2022 Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference - Inozyme Pharma (NASDAQ:INZY) - Benzinga
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. INZY , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a fireside chat ...
Benzinga
12/1/2022 Stock Market | Finance
BOSTON, Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA ...
azcentral.com
11/10/2022 Stock Market | FinancialContent Business Page
... ongoing ENPP1 Deficiency trial, improving patient convenience. In parallel, we remain focused on initiating a clinical trial in pediatric patients with ENPP1 Deficiency,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president and chief executive officer. ‚AuOur partnerships with leading disease experts and research organizations continue to yield ...
financialcontent.com
11/10/2022 Inozyme Pharma (INZY) Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
... ongoing ENPP1 Deficiency trial, improving patient convenience. In parallel, we remain focused on initiating a clinical trial in pediatric patients with ENPP1 Deficiency,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president and chief executive officer. ‚AuOur partnerships with leading disease experts and research organizations continue to yield ...
researchpool.com
11/7/2022 Inozyme Pharma to Participate in Upcoming Investor
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in ...
Globe Newswire
11/7/2022 Inozyme Pharma to Participate in Upcoming Investor Conferences
Inozyme Pharma Inc. BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer ...
Yahoo News
11/7/2022 2022-11-07 | NDAQ:INZY | Press Release | Inozyme Pharma Inc.
INZY 23 minutes ago BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief ...
stockhouse.com
11/7/2022 Inozyme Pharma to Participate in Upcoming Investor Conferences - Inozyme Pharma (NASDAQ:INZY) - Benzinga
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. INZY , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in the following ...
Benzinga
11/6/2022 Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$11m market cap decline means a loss of US$268k for insiders who bought this year
... Pharma Inozyme Pharma Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Co-Founder Axel Bolte for US$250k worth of shares, at about US$3.69 per share. That means that even when the share price was higher than ...
Yahoo News
9/6/2022 Inozyme Pharma to Present at H.C. Wainwright 24th Annual
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment ...
Globe Newswire
6/16/2022 Inozyme Pharma Announces Partnership with Rady Children's
... trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com . About ENPP1 Deficiency ENPP1 ...
Globe Newswire
6/7/2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical
... and government relations. ‚AuIt is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme's clinical development and regulatory strategy,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and chief executive officer. ‚AuKurt's experience across the entirety of the drug development process will ...
Globe Newswire
6/7/2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer
... and government relations.‚AuIt is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme's clinical development and regulatory strategy,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and chief executive officer. ‚AuKurt's experience across the entirety of the drug development process will ...
onenewspage.com
6/7/2022 2022-06-07 | NDAQ:INZY | Press Release | Inozyme Pharma Inc.
... government relations. ‚AuIt is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme’s clinical development and regulatory strategy,” said Axel Bolte, MSc, MBA, Inozyme’s co-founder, president, and chief executive officer. ‚AuKurt’s experience across the entirety of the drug development ...
stockhouse.com
6/1/2022 Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference
... GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference. The presentation will take ...
onenewspage.com
5/3/2022 2022-05-03 | NDAQ:INZY | Press Release | Inozyme Pharma Inc.
INZY 1 hour ago BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the ...
stockhouse.com
4/22/2022 Axel Bolte Acquires 67,750 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) Stock - Ticker Report
Inozyme Pharma, Inc. ( NASDAQ:INZY ‚Ai Get Rating ) CEO Axel Bolte acquired 67,750 shares of the stock in a transaction dated Tuesday, April 19th. The shares were bought at an average price of $3.69 per share, with a total value of $249,997.50. Following the completion of the transaction, the chief ...
Ticker Report
4/21/2022 Inozyme Pharma surges 17% following disclosure of several insider buys
... Editor - Shares of Inozyme Pharma surged 17% on Thursday after SEC filings indicated stock purchases by company executives and a director. - On April 19, CEO [Axel Bolte] bought 67,750 shares at a price of $3.69 for a purchase price of ~250K. - On the same date, CFO [Sanjay Subramanian] and COO ...
Seeking Alpha
4/21/2022 Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Axel Bolte Purchases 67,750 Shares
Inozyme Pharma, Inc. ( NASDAQ:INZY ‚Ai Get Rating ) CEO Axel Bolte bought 67,750 shares of the company's stock in a transaction that occurred on Tuesday, April 19th. The stock was purchased at an average cost of $3.69 per share, with a total value of $249,997.50. Following the acquisition, the ...
zolmax.com
4/20/2022 Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Axel Bolte Buys 67,750 Shares
Inozyme Pharma, Inc. ( NASDAQ:INZY ‚Ai Get Rating ) CEO Axel Bolte bought 67,750 shares of Inozyme Pharma stock in a transaction that occurred on Tuesday, April 19th. The stock was purchased at an average price of $3.69 per share, with a total value of $249,997.50. Following the purchase, the chief ...
etfdailynews.com
4/12/2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency
... Deficiency, we believe we are another step closer to potentially bringing a much-needed therapeutic option to patients suffering from these devastating diseases,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, President, and Chief Executive Officer. ‚AuIn preclinical models of ABCC6 Deficiency and ENPP1 Deficiency, INZ-701 increased ...
drug-dev.com
4/12/2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical
... Deficiency, we believe we are another step closer to potentially bringing a much-needed therapeutic option to patients suffering from these devastating diseases,‚Au said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and chief executive officer. ‚AuIn preclinical models of ABCC6 Deficiency and ENPP1 Deficiency, INZ-701 increased ...
Globe Newswire